TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1379054

Group type: EXPERIMENTAL
Intervention: Clemastine 2 mg twice a day for 5 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once a day for 5 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clemastine and Loratadine
Number of subjects: 15
Study: 6741683

Group type: EXPERIMENTAL
Intervention: Mouth anesthesia with 2% lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouth and pharyngeal anesthesia with 2% lidocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upper and lower airway anesthesia with 2% lidocaine and inhalation of 4% lidocaine (60 breaths)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study: 30582246

Group type: EXPERIMENTAL
Intervention: 17% EDTA solution + Saline solution (SSE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.25% Ca(OCl)2 (CH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl (SH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl + 17% EDTA (SHE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.25% Ca(OCl)2 + 17% EDTA (CHE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline solution (SS) (control)
Number of subjects: 60
Study: 27918778

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 25810108

Group type: EXPERIMENTAL
Intervention: Stimulating catheter
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 58
Study: 24555913

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA 1 g/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 22241059

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (8 weeks)
Number of subjects: 16
Study: 19574865

Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) 15 mg administered alone
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) 15 mg administered 15, 30, or 60 mins after bupivacaine (20 mL 0.25%)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Extended-release epidural morphine (EREM) groups (with/without prior bupivacaine)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Bupivacaine + placebo (normal saline) administered 15, 30, or 60 mins after bupivacaine
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Groups receiving EREM after bupivacaine
Number of subjects: 144
Study: 17301625

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1351
Study: 15121929

Group type: EXPERIMENTAL
Intervention: Prophylactic application of emollient ointment twice a day through day 14 (P)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Routine skin care (R)
Number of subjects: 1191
Study: 11213858

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reteplase and Tenecteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current trials
Number of subjects: 0
Study: 9656196

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: CHOP/VIA
Number of subjects: 132
Study: 8003791

Group type: EXPERIMENTAL
Intervention: 0.3% podophyllotoxin cream
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin cream
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.3% and 0.5% podophyllotoxin creams
Number of subjects: 150
Study: 2523681

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulized solution 0.4 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulized solution 0.6 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ipratropium bromide metered-dose inhaler 40 micrograms
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide nebulized solution 0.4 mg and 0.6 mg
Number of subjects: 42
Study: 304691

Group type: EXPERIMENTAL
Intervention: Kallikrein inhibitor (protease-inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no kallikrein inhibitor)
Number of subjects: 0
Study: 31668142

Group type: EXPERIMENTAL
Intervention: Fascial Manipulation® (FM®) method, 3 weekly sessions by PtA
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study: 31192505

Group type: EXPERIMENTAL
Intervention: Genetic testing for T1D susceptibility SNPs or family history screening, followed by participation in a randomized controlled trial for tolerance induction with oral insulin.
Number of subjects: 330000

Group type: EXPERIMENTAL
Intervention: Randomized controlled trial for tolerance induction with oral insulin.
Number of subjects: 330000

Group type: EXPERIMENTAL
Intervention: Screening program GPPAD-02.
Number of subjects: 330000
Study: 28784729

Group type: EXPERIMENTAL
Intervention: $50 cash incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: $25 cash incentive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: $0 cash incentive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonincentivized control group
Number of subjects: 0
Study: 23963636

Group type: EXPERIMENTAL
Intervention: Home-based walking intervention plus brief telephone counseling (n = 20)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Wait-list control group (n = 12)
Number of subjects: 32
Study: 24560287

Group type: EXPERIMENTAL
Intervention: Individualized Arterial Input Function (iAIF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cohort-based Arterial Input Function (cAIF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: iAIF
Number of subjects: 17
Study: 22563179

Group type: EXPERIMENTAL
Intervention: Transnasal ileus tube
Number of subjects: 186

Group type: COMPARATOR
Intervention: Nasogastric tube (NGT)
Number of subjects: 186
Study: 19349586

Group type: EXPERIMENTAL
Intervention: Guided Care Program for Families and Friends (GCPFF)
Number of subjects: 308
Study: 17189867

Group type: EXPERIMENTAL
Intervention: Rosiglitazone + Insulin
Number of subjects: 53
Study: 15108771

Group type: EXPERIMENTAL
Intervention: Standard tacrolimus (trough levels of 10-15 ng/mL) plus reduced sirolimus (trough levels of 5-10 ng/mL) (Group I)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Reduced tacrolimus (trough levels of 5-10 ng/mL) plus standard sirolimus (trough levels of 10-15 ng/mL) (Group II)
Number of subjects: 39
Study: 11393298

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9730094

Group type: EXPERIMENTAL
Intervention: 2 hours in a supine lying-down position with 30 degrees of arm elevation
Number of subjects: 45

Group type: COMPARATOR
Intervention: No arms-at-side lying-down position after 2 hours awake or overnight sleep with bed-head elevated or not
Number of subjects: 45
Study: 7506878

Group type: EXPERIMENTAL
Intervention: Aspartame (APM) 34 mg/kg single morning dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aspartame (APM)
Number of subjects: 10
Study: 3174150

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 417375

Group type: EXPERIMENTAL
Intervention: Marijuana intoxication
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal waking state (without marijuana)
Number of subjects: 35
Study: 31722839

Group type: EXPERIMENTAL
Intervention: Rd (lenalidomide, dexamethasone)
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Vd (bortezomib, dexamethasone)
Number of subjects: 1265

Group type: COMPARATOR
Intervention: Control arm of hallmark RCTs
Number of subjects: 1265
Study: 30315423

Group type: EXPERIMENTAL
Intervention: TiF4 varnish
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Duraphat® (fluoride positive control)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo varnish (no fluoride)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (negative control)
Number of subjects: 60
Study: 28493912

Group type: COMPARATOR
Intervention: no-exercise control (n = 51)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: low-amount, low-intensity exercise (LALI, n = 38)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: high-amount, low-intensity exercise (HALI, n = 52)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: high-amount, high-intensity exercise (HAHI, n = 30)
Number of subjects: 171
Study: 26114436

Group type: EXPERIMENTAL
Intervention: cART
Number of subjects: 836
Study: 23616552

Group type: EXPERIMENTAL
Intervention: Multisensory signals (audiovisual signals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unisensory conditions
Number of subjects: 0
Study: 21267525

Group type: EXPERIMENTAL
Intervention: n‐3 LCPUFA supplementation (2.5 g/day, with 1.67 grams of EPA and 0.83 grams of DHA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 19125899

Group type: EXPERIMENTAL
Intervention: Nateglinide + Metformin
Number of subjects: 248

Group type: COMPARATOR
Intervention: Glibenclamide + Metformin
Number of subjects: 248
Study: 17420152

Group type: EXPERIMENTAL
Intervention: comfilcon A
Number of subjects: 45

Group type: COMPARATOR
Intervention: lotrafilcon A
Number of subjects: 45

Group type: COMPARATOR
Intervention: balafilcon A
Number of subjects: 45
Study: 15023101

Group type: EXPERIMENTAL
Intervention: Milrinone infusion (0.5 microg.min(‐1).kg(‐1))
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 62
Study: 10694619

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g in 100 mL of saline solution)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 9179457

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (150 mg daily for 30 days)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 8472140

Group type: EXPERIMENTAL
Intervention: Monofilament continuous absorbable sutures (Maxon)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Multifilament interrupted absorbable sutures (Vicryl)
Number of subjects: 988
Study: 3911096

Group type: EXPERIMENTAL
Intervention: 1 mg guanfacine hydrochloride (Estulic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine hydrochloride (Estulic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine (Catapres)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.3 mg clonidine (Catapres)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31176601

Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine chemoradiation
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Complete/marked response group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Moderate response group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Minimal response group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pathologic complete responses
Number of subjects: 71
Study: 29505517

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (fasting, decompression, intravenous somatostatin)
Number of subjects: 40
Study: 26909012

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment with ibuprofen
Number of subjects: 386

Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 386

Group type: COMPARATOR
Intervention: Non-antibiotic treatment
Number of subjects: 386
Study: 24925675

Group type: EXPERIMENTAL
Intervention: RYO cigarettes
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: PMM cigarettes
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: FM cigarettes
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: All cigarette types
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MYO cigarettes (RYO and PMM)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: MYO and FM cigarettes
Number of subjects: 77
Study: 22845032

Group type: EXPERIMENTAL
Intervention: HIV education, peer video, motivational interviewing, behavioral skills training
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 73
Study: 21071584

Group type: EXPERIMENTAL
Intervention: Web-guided 'Constant-care' approach
Number of subjects: 333

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 333
Study: 18265663

Group type: EXPERIMENTAL
Intervention: Ligasure electrocautery device
Number of subjects: 116
Study: 16373244

Group type: EXPERIMENTAL
Intervention: Red clover isoflavone supplement (80 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12196430

Group type: EXPERIMENTAL
Intervention: Clinic and community intervention (group A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clinic only intervention (group B)
Number of subjects: 200
Study: 9568917

Group type: EXPERIMENTAL
Intervention: Febrile episodes
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Increase in temperature (Celsius) during subsequent infections
Number of subjects: 180

Group type: COMPARATOR
Intervention: Age, sex, type of initial seizure, temperature during initial seizure, family history of febrile seizures or epilepsy
Number of subjects: 180
Study: 8534629

Group type: EXPERIMENTAL
Intervention: Kabi 2161 (600 mg) tablets, 1 four times daily
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Kabi 2161 (600 mg) tablets, 2 twice daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 1978612

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Esmolol 1.5 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no esmolol)
Number of subjects: 40
Study: 64653

Group type: EXPERIMENTAL
Intervention: Heparin analogue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study: 30747746

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 31605312

Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 158
Study: 31012933

Group type: EXPERIMENTAL
Intervention: Augmented nurse home visitation program with IPV intervention (n=229 participants)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Standard nurse home visitation program (n=263 participants)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Both groups (Augmented and Standard)
Number of subjects: 492
Study: 28589749

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 25765456

Group type: EXPERIMENTAL
Intervention: 30 s treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1 min treatment
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 min treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 16
Study: 23719582

Group type: EXPERIMENTAL
Intervention: ARCON (accelerated radiotherapy with carbogen breathing and nicotinamide)
Number of subjects: 261

Group type: COMPARATOR
Intervention: AR (accelerated radiotherapy alone)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: ARCON
Number of subjects: 261
Study: 21827652

Group type: EXPERIMENTAL
Intervention: Chest compressions with good quality (compression depth ≥ 40 mm, compression rate 100‐120/minute)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Chest compressions with bad quality (initial compression depth < 40 mm, initial compression rate < 100 or > 120/minute)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Chest compressions with decay (change from good to bad during the 12 minutes)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: No-flow ratio (NFR) during ALS
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Decay of chest compression quality within the first two minutes
Number of subjects: 57
Study: 19273696

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin with fluorouracil (PCF)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin without fluorouracil (PC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: INT0116 (standard treatment)
Number of subjects: 78
Study: 18090457

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 200

Group type: COMPARATOR
Intervention: All SSRIs
Number of subjects: 200
Study: 15673181

Group type: EXPERIMENTAL
Intervention: Rote rehearsal during divided attention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rote rehearsal
Number of subjects: 0
Study: 11246607

Group type: EXPERIMENTAL
Intervention: Low microparticle diet (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet (n = 10)
Number of subjects: 20
Study: 12017931

Group type: EXPERIMENTAL
Intervention: Arm & Hammer Dental Care (high baking-soda concentration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm & Hammer PeroxiCare (high baking-soda concentration)
Number of subjects: 0
Study: 8316346

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 450-750 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3548521

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31166248

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone (DEX) implant
Number of subjects: 14

Group type: COMPARATOR
Intervention: Topical dorzolamide
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravitreal DEX implant at Month 6
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Study eyes
Number of subjects: 14
Study: 29696669

Group type: EXPERIMENTAL
Intervention: Multidisciplinary collaborative care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27958690

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 300 µg, two injections prior to BM-MNC transplantation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 44
Study: 26149149

Group type: EXPERIMENTAL
Intervention: Hand touch training (H group)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Short-term pressure gauge training (G group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison between H group and G group for target pressure 60 cmH(2)O
Number of subjects: 41
Study: 23193016

Group type: EXPERIMENTAL
Intervention: Long-term shiftwork
Number of subjects: 20

Group type: COMPARATOR
Intervention: Day workers
Number of subjects: 20
Study: 22352262

Group type: EXPERIMENTAL
Intervention: Basic treatment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid plus basic treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Healthy gingiva (control group)
Number of subjects: 130
Study: 18422632

Group type: EXPERIMENTAL
Intervention: Probiotic strains (2 x 10(10) CFU)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 83
Study: 17186796

Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% and tacrolimus 0.1% ointments
Number of subjects: 82

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 82
Study: 15041271

Group type: EXPERIMENTAL
Intervention: Heparin-coated stent implantation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 47
Study: 10334351

Group type: EXPERIMENTAL
Intervention: Single fraction radiation (750 centigray)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 27
Study: 8916055

Group type: EXPERIMENTAL
Intervention: Surgical clipping using fronto-temporal and Dolenc approaches
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 54
Study: 1871540

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg intravenous injection every 12 hours until the 3rd postoperative day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7051246

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ; 160 mg of TMP and 800 mg of SMZ) twice daily for 21 days
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 147
Study: 29850990

Group type: EXPERIMENTAL
Intervention: Probiotic (PRP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (PLP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study: 28671090

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 1000
Study: 26363312

Group type: EXPERIMENTAL
Intervention: Immediate release oxycodone (20 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no drug administered)
Number of subjects: 49
Study: 23608249

Group type: EXPERIMENTAL
Intervention: Lowest vitamin D quartile (1-15.9 ng/ml)
Number of subjects: 936
Study: 21915572

Group type: EXPERIMENTAL
Intervention: PTH 1-84 (100 µg once daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no PTH 1-84)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: PTH 1-84
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study: 19820390

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation
Number of subjects: 90
Study: 17120865

Group type: EXPERIMENTAL
Intervention: Video Inter‐Active (VIA) method; duration 5 weeks
Number of subjects: 0
Study: 14687899

Group type: EXPERIMENTAL
Intervention: Fibrate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-drug treatment
Number of subjects: 0